GLP-1 agonists are a class of medications that help regulate blood sugar, increase fullness (satiety), and slow stomach emptying, leading to weight loss and improved glucose control for type 2 diabetes and obesity.
“Studies indicate that GLP-1 (like semaglutide) and glucose-dependent insulinotropic polypeptide (GIP) therapies may lead to lean body mass loss at 25 to 40 per cent of total weight reduction,” the companies said.
They added that Indian patients could potentially be at higher risk due to lower protein intake, lower baseline muscle mass, and higher body fat levels, highlighting the need to actively address muscle health.
“GLP-1 therapies represent a significant advancement in diabetes and obesity management. However, a clear unmet need remains in supporting patients beyond pharmacological treatment, particularly in addressing nutrition gaps and preserving muscle health during therapy,” said M V Ramana, chief executive officer (CEO) for global generics at DRL.
The JV added that with GLP-1- and GIP-based therapies becoming more widely adopted in the management of type 2 diabetes and obesity, it has become increasingly important to build an integrated ecosystem beyond medication.
According to reports, an estimated 1.6 million people in India are currently on GLP-1 or GIP treatment.
With clinical guidelines recommending a daily protein intake of 1.2 to 1.5 grams per kilogram of body weight during therapy to help preserve muscle mass, the JV said that Celevida GLP+ is custom-designed to bridge nutritional gaps and support muscle maintenance for people on GLP-1 and GIP therapy.
“With Celevida GLP+, we aim to address this gap through a targeted, science-backed nutritional solution that complements pharmacological therapies and supports better overall patient outcomes in their everyday journey,” Ramana said.
 "diabetes")